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Abstract 
 
 
 
Background—Uterine leiomyomas, or fibroids, are prevalent tumors that are dependent 
on sex steroids for growth. Clinically, progesterone promotes fibroid growth and anti-progestins 
cause a durable reduction in fibroid size, yet the mechanisms underlying progesterone action are 
unclear. A-kinase anchoring protein 13 (AKAP-13, also known as AKAP-Brx) functions as a 
Rho-GEF and is over-expressed in fibroids. AKAP-Brx has been shown to activate estrogen and 
glucocorticoid receptors, and bind these receptors via a nuclear receptor-binding motif. However, 
it is not known whether AKAP-Brx also binds progesterone receptor or augments progesterone 
action. Objective—The purpose of this study was to determine if AKAP-Brx affected the activity 
of progesterone receptor B (PR-B), the more active isoform of the nuclear progesterone receptors. 
Design—Controlled laboratory research studies. Results—AKAP-Brx more than doubled 
progesterone-dependent gene activation by PR-B in two cell lines, including Cos7 cells and 
immortalized fibroid cells, and for two hormone dependent promoters. On the contrary, silencing 
of AKAP-Brx via RNA interference reduced progesterone dependent gene activation of 
endogenous PR-B-controlled-genes in a dose-dependent manner. In vitro and ex vivo binding 
studies suggest that AKAP-Brx and PR-B interact directly. Inhibition of MEK reduced AKAP-
Brx enhancement of PR-B activity, suggesting that AKAP-Brx may affect PR-B via a pathway 
involving p44/42 MAPK (ERK1/2) phosphorylation. Inhibition of p38 MAPK, on the other hand, 
did not affect PR-B activation by AKAP-Brx. Conclusion—This is the first report that AKAP-Brx 
augments gene activation by PR-B in a ligand-dependent manner in various cell types, including 
fibroids. AKAP-Brx may bind directly to PR-B and enhance its activity via ERK1/2 
phosphorylation. These data suggest that the increased expression of AKAP-Brx in fibroids could 
promote progesterone-mediated fibroid growth. 
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Introduction 
 
 
Uterine leiomyomas, or fibroids, are prevalent benign growths in the uterus that 
represent a significant health problem for millions of women.  Grossly, uterine fibroids 
are large, stiff, rubbery masses that are dependent on sex steroids for growth. While the 
cause of uterine fibroids remains unclear, clinically, high-progesterone states such as 
pregnancy promote fibroid growth.
1-4
 Treatment of women with progesterone results in 
increased cellularity and mitotic activity in the leiomyomas,
5
 whereas the synthetic anti-
progestin mifepristone
6-9
 and selective-progesterone-receptor-modulators (SPRMs) like 
Asoprisnil (J687)
10,11
 and Ulipristal (CDB-2914)
12-15
 cause a durable reduction in fibroid 
size in a significant proportion of treated women. In vitro effects of anti-progestins 
include reduced proliferation, induction of apoptosis, reduction of extracellular matrix 
deposition, and reduction of growth factor expression, suggesting a clear link between 
progesterone and fibroid growth.
12,16
  
The effects of progesterone in the uterus and other reproductive tissues are due to 
changes in gene expression modulated by the progesterone receptors (PRs). PRs are 
members of the nuclear hormone receptor superfamily of transcription factors. After 
being activated by binding progesterone, PRs activate transcription of hormone-
responsive genes. Nuclear PRs exist in two isoforms, designated PR-A and PR-B. PR-B 
is traditionally considered to be the more active isoform in most PR sensitive tissues
17,18
 
and differs from PR-A solely in the presence of an additional 164 amino acids at its N 
terminal.
19,20
 The PRs are modular transcription factors containing two transcription 
activation functions, AF-1 located in the N-terminal A/B domain, and AF-2 located 
within the C-terminal ligand-binding domain.
21
 PR-B contains a third activation function, 
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AF-3, in its unique N-terminal region.
19
 In addition to the direct actions of progesterone, 
extracellular growth factors greatly influence PR signaling in the presence of 
progestins.
22,23
 This pathway involves signaling from cell surface receptors and results in 
phosphorylation of the progesterone receptor by mitogen activated kinases (MAPKs).
24
 
Specifically, activation of PR by serum growth factors has been shown to involve 
phosphorylation of serine 294 in the AF-1 region of PR through a Ras-Raf-MAPK 
signaling pathway.
25
 Such MAPK-dependent phosphorylation is thought to augment 
ligand-dependent transcriptional activation by PR, thereby enhancing the genomic effects 
of PR. Of note, MAPK expression is elevated in many solid tumors
26,27
 and may play a 
role in progesterone-mediated tumor growth. 
 In addition to soluble signaling by sex steroids, the importance of mechanical 
signaling through extracellular matrix (ECM) – cell interactions has been increasingly 
recognized as a major player in uterine physiology and pathophysiology. The 
extracellular matrix is the main intermediary that conveys mechanical forces to the cell 
membrane and from there to the intracellular space.
28
 In stiff tissues, which include many 
tumors, exogenous forces (imposed by stiff matrices) and endogenous forces 
(cytoskeletal tension) are functionally linked via Rho/ROCK/MAPK pathways.
29
 
Specifically, matrix stiffness induces activation of membrane integrins,
30
 which in turn 
activate RhoA. RhoA (often referred to simply as Rho) belongs to the Rho family of 
small G-proteins. Small G-proteins are classified into five subgroups, the Ras, Ran, Rab, 
Sar/Arf, and Rho families.
30
 The Rho family proteins, which include RhoA, Cdc42, and 
Rac1, play an important role in cell morphology, adhesion, motility and growth after their 
activation by numerous extracellular stimuli.
30-32
 When RhoA is activated by integrins, it 
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propagates a signaling cascade that involves the activation of Rho-associated protein 
kinase (ROCK) and subsequently myosin light chain (MLC), leading to the formation of 
actin-myosin stress fibers and enhanced cell contractility.
31,32
 The resultant cytoskeletal 
tension feeds back to the cell membrane to promote assembly of focal adhesion (FA) 
complexes which help anchor the cell to the ECM.
33
 Cytoskeletal tension also drives 
focal adhesion proteins to modify growth factor signaling through the mitogen-activated 
kinase ERK 1/2—a modulator of cell growth.34,35 Thus, Rho indirectly drives ERK 
dependent growth.
29
 Reciprocally, ERK can also induce ROCK and myosin light chain 
activity.
36,37
 Finally, not only do cells respond to mechanical cues from the ECM, they 
also help maintain and remodel the ECM through secretion of the various ECM 
components and the molecules that degrade them, setting up a feedback loop of 
reciprocal ECM-cellular interactions. 
 In fibroids, the ECM is excessive in amount and abnormal in content and 
organization, leading to increased stiffness.
38
 Additionally, our group has recently found 
that cells within a leiomyoma have an altered mechanical response to applied stress: 
when normal myometrial cells are stressed, the cells orient perpendicular to the axis of 
stress.
39
 Fibroid cells, on the other hand, fail to reorient their actin cytoskeleton in 
response to applied stress. This implies that fibroid cells do not adequately perceive or 
respond to mechanical queues, suggesting impairment in mechanical sensing. Thus, 
fibroids have an abundant, abnormal and stiff ECM, but, paradoxically, the cells within 
fibroids do not perceive that mechanical stiffness. These observations have led us to 
postulate that attenuated mechanical sensing may contribute to fibroid pathogenesis by 
creating a feed-forward cycle of excessive ECM deposition and growth.  
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At the molecular level, the altered response to stress apparent in fibroids is 
characterized by altered signaling of RhoA and over-expression of the Rho-GEF protein 
Brx.
38,39
 Rho proteins, like other small G-proteins, exist in active GTP-bound and 
inactive GDP bound forms,
40,41
 turning on and off the activity of their target molecules 
via physical interactions.
40
 Guanine nucleotide exchange factors (GEFs), which contain 
specific protein motifs characterized by the Dbl homology (DH) domain followed by the 
pleckstrin homology domain, catalyze the conversion of the GDP-bound to the GTP-
bound form, indicating that this class of proteins plays an essential role in the activation 
of small G-proteins.
42,43
 After regulating the activity of their target molecules, GTP-
bound small G-proteins are immediately returned to the GDP-associated form via their 
intrinsic GTPase activity.
40
 Brx (Breast Cancer Auxiliary Factor) belongs to the Dbl 
family of proto-oncogenes (reviewed in 
44
) that function as guanine nucleotide exchange 
factors (GEFs) for Rho-GTPases. Its over-expression in fibroids shifts the balance of 
Rho-GDP/Rho-GTP to the active, GTP bound states and thus promotes RhoA-mediated 
fibroid growth.  
 Interestingly, Brx not only acts as a Rho family GEF but also binds to nuclear 
hormone receptors via its C-terminal portion (nuclear receptor-interacting domain 
(NRID)), which contains an leucine-rich LXXLL motif, and enhances transcriptional 
activity of the estrogen receptors alpha
45
 and beta
46
 as well as the glucocorticoid 
receptor.
47
 AKAP-Brx (also known as AKAP13) is a larger splicing variant of Brx 
containing an additional 1389 amino-acid residues.
48
 This transcript possesses a protein 
kinase A docking domain in its N-terminal portion and a full Brx sequence-containing 
GEF domain and NRID at its C-terminal half.
48
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 In sum, both soluble signals, notably via the proliferative effects of estrogen and 
progesterone, and mechanical signals, transduced from the extracellular matrix through 
Rho-mediated pathways, are important for fibroid growth. AKAP-Brx, which is over-
expressed in fibroids, is a unique protein in that it participates in both soluble and 
mechanical signaling pathways. Collectively, these observations suggest that AKAP-Brx 
could serve to integrate nuclear hormone receptor signaling with Rho-mediated 
mechanical signaling in the uterus, and that dysregulated expression of the protein could 
play a role in fibroid growth. However, despite what is already known about the 
interaction of AKAP-Brx with the estrogen receptors, it is not known whether AKAP-Brx 
also binds to progesterone receptor or augments progesterone action.  
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Purpose and Specific Aims 
 
  As it is not known whether AKAP-Brx binds to progesterone receptor or 
augments progesterone action, the present study was performed to investigate the effect 
of AKAP-Brx on PR-B. Three specific aims were proposed: 
- Specific Aim 1: To test whether AKAP-Brx affects progesterone-dependent 
gene regulation in leiomyoma cells.   
- Specific Aim 2: To test whether AKAP-Brx interacts with progesterone 
receptor directly. 
- Specific Aim 3: To investigate putative mechanisms through which AKAP-
Brx would enhance PR-B activity, specifically via MAPK phosphorylation 
pathways. 
. 
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Methods 
 
 
 
All experiments were conducted by the author unless otherwise noted. 
Plasmids— Progesterone-Response-Element luciferase (PRE-luciferase) and the 
basal promoter TA-luciferase were purchased from Signosis. MMTV-luciferase, in which 
the luciferase gene is under the control of a progesterone-responsive murine mammary 
tumor virus (MMTV) promoter,
49,50
 and its associated basal promoter control (TK-
luciferase), were provided by Dr. Tomoshige Kino (NICHD, NIH, Bethesda, MD). 
Expression plasmids for full-length AKAP-Brx were previously described.
46
 Human 
progesterone receptor B (hPR-B) expressing plasmid was a generous gift of Dr. Stoney 
Simons (NIDDK, NIH, Bethesda, MD). The empty bacterial expression vectors 
pcDNA4-HisMax and pSG5 used as negative controls (for AKAP-Brx and PR-B, 
respectively) are commercially available through Invitrogen and Agilent Technologies. 
Expression of transfected proteins was confirmed via Western blot of transfected cell 
lysates (data not shown).  
Cell culture—African green monkey kidney COS7 cells were obtained from 
American Type Culture Collection (ATCC) (Manassas, VA) and grown in Dulbecco’s 
Modified Eagle Medium (DMEM) (GIBCO - Invitrogen) supplemented with 10% fetal 
bovine serum (Fischer - Thermo Scientific), 100 units of penicillin, 1 ᶙg/ml of 
streptomycin sulfate, and 2 mM L-glutamine (Invitrogen). Human breast carcinoma 
T47D cells were also obtained from ATCC and grown in RPMI1640 (GIBCO – 
Invitrogen) with the same supplements. Immortalized fibroid cell line was generated as 
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described previously
51
 and grown in DMEM/F12 (GIBCO – Invitrogen) with the same 
supplements. 
Transient Transfection— Twenty-four hours before transfection, cells were 
seeded in 24-well plates and grown to ~50% confluence in phenol-red free, 10% 
charcoal-stripped fetal bovine serum preparations of the appropriate growth medium for 
each cell type. Transfection was performed with FuGENE 6 (Roche Applied Science) or 
HilyMax5 (Dojindo) per the manufacturer’s directions. The cells were co-transfected 
with 0.3-0.5 ug/well of reporter plasmid, 0.3-0.5 ug/well of AKAP-Brx and 25 ng/well of 
hPR-B expression plasmids. Total DNA was kept constant by addition of empty vector. 
Twenty-four hours after transfection, 40 nM progesterone or EtOH vehicle dissolved in 
medium was added to the cells. After an additional 24 h the cells were lysed with a 
reporter lysis buffer (Promega), and the luciferase activities were determined using a 
GloMax 96 Microplate Luminometer (Promega). Luciferase activities were normalized 
by protein assay (Bradford, BioRad). The author acknowledges Tiffany Chu for her help 
performing protein assays. 
MAPK Inhibition Studies—Cells were seeded in 24-well plates and transfected as 
described above. After transfection but prior to addition of hormone, cells were pre-
treated with the appropriate inhibitor: p38 MAPK inhibitors (2 uM SB202190 or 10 uM 
SB203580 dissolved in DMSO) or a MEK 1/2 inhibitor (0.1, 1 or 10 uM UO126 
dissolved in DMSO) for 1 hour. All inhibitors were purchased from Calbiochem. A 
control group was treated with equivalent amounts of DMSO. After 1 hour of pre-
treatment, progesterone was added to each well to a final concentration of 40 nM without 
changing the medium. After an additional 24 hours of progesterone treatment, cells were 
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lysed and assayed as described above.  The following experiments were conducted to 
validate the activity of each inhibitor:  
p38 MAPK inhibitors: Cos7 cells were seeded in 6-well plates and grown to 50% 
confluence.  Cells were then treated for an hour with the appropriate inhibitor or DMSO, 
after which they were shocked with 50% sorbitol for 30 minutes, which is known to 
induce phosphorylation of p38 MAPK.
52
 Cells were extracted and lysates resolved via 
SDS-PAGE. Gels were blotted onto PVDF membranes and probed with anti- p38 MAPK 
antibodies (phosphorylated and pan). Immune complexes were detected using enhanced 
chemiluminescence (Pierce) as per manufacturer's directions. Relative protein 
concentrations in the presence and absence of inhibitor were analyzed via densitometry.  
MEK 1/2 inhibitors: Cos 7 cells were seeded in 6-well plates and grown to 50% 
confluence in serum-free media. Cells were then treated with 1 uM UO126 or DMSO for 
one hour. Serum was subsequently reintroduced to the medium to induce p42/44 MAPK 
(ERK 1/2) activation. Cells lysates were resolved in SDS ± PAGE, blotted to PVDF and 
probed with anti-phosphorylated p42/44 MAPK (ERK1/2) antiserum. Protein 
concentrations in the presence and absence of inhibitor were analyzed via densitometry.  
siRNA Interference—These experiments were conducted by Dr. Paul H. Driggers. 
T47D human breast-cancer cells were employed for these experiments as they retain 
endogenous PR-B expression after immortalization. T47D cells were seeded in 24-well 
plates and grown to 30-50% confluence in phenol-red-free media supplemented with 
charcoal stripped serum (without antimicrobials). Cells were transfected with 20 pmol 
AKAP-Brx siRNA per well or equal amounts of scrambled siRNA. Transfection was 
performed with Lipofectamine (Invitrogen). After 24 hours, increasing amounts of 
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progesterone (0, 0.5, 1.0, 5.0, 10, 20 or 40 nM) were added to respective wells. Cells 
were lysed and assayed for activity of the PR-controlled gene alkaline phosphatase after 
24 hours.  
GST-binding studies—Full transcript AKAP-Brx (termed FT) or a 1.8 kb 
fragment corresponding to region 5 (near the C terminal) of AKAP-Brx (termed R5) were 
sub-cloned in-frame into the bacterial expression plasmid pGEX2TKB. Recombinant 
GST-FT, GST-N5 and GST-0 control proteins were induced and purified as per 
manufacturer's instructions (Pharmacia). PR constructs were generated by PCR 
amplification from the pSG5-hPR-B plasmid using the following oligonucleotides: (1): 5' 
CGAAATTAATACGACTCACTATAGGGAGACCCACCATGGTGCTGATCAACCT
GTTAATGAGC 3', and (2) 5' TCACATCTTTTTATGAAAGAGAAGGGG 3'. The 
forward primer contained a T7 sequence for recognition by rabbit reticulocyte RNA 
polymerase. Fragments were then transcribed and translated in vitro (TNT, Promega). 
100 000 c.p.m. of 35S-labeled PR protein constructs were incubated with GST-construct-
coated beads for 1 h at 4°C in HBB (40mM HEPES, 75 mM KCl, 0.5 mM EDTA, 5 mM 
MgCl2, 1 mM DTT, 1 mM AEBSF, bovine serum albumin 0.5 mg/ml, and 0.05% nonidet 
P40). After five wash steps in HBB, bound proteins were eluted in sample buffer and 
analysed by SDS ±PAGE and auto-radiography. 10 000 c.p.m. were loaded for each input 
lane. The luciferase protein, which does not bind to AKAP-Brx, was in vitro transcribed-
translated using a template provided by the manufacturer (TNT, Promega) and served as 
a negative control. In vitro transcribed-translated estrogen receptor (ER) was used as a 
positive control, as it has been shown to bind AKAP-Brx in past experiments.
45
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Mammalian Two Hybrid Plasmids—The GAL4-luciferase reporter was 
constructed by amplification of GAL45E1b promoter sequences from pGAL45E1bCAT 
and subcloned into pGL2-Basic (Promega) as previously described.
45
 DBD (pM) empty 
vector and AD (VP16) empty vector were obtained commercially (Matchmaker 
Mammalian Assay Kit, Clontech). A 738 base pair fragment of PR corresponding to 
amino acids 687 through 933 of the C terminal of PR (termed PR687C) was created by 
PCR amplification from the full length hPR-B plasmid using the following primers: (1) 
5’ AGCGGCGAATTCCTGATCAACCTGTTAATGAGC 3’ and (2) 5’ 
CCCCGGGAATTCTCACTTTTTATGAAAGAGAAG 3’. The forward primer contains 
an XbaI recognition sequence followed by a Kozak sequence and the appropriate base 
pairs of hPR-B cDNA. The reverse primer contains the EcoRI recognition sequence, 
Kozak sequence and the appropriate base pairs of hPR-B cDNA. The PCR amplification 
product was subcloned into the commercial DBD empty vector via XbaI / EcoRI sites 
and the resultant vector transformed into competent cells. Recombinants were isolated via 
analytic gel electrophoresis and these were further digested to confirm correct 
directionality.  
A 2.1 kb PR fragment corresponding to amino acids 1 through 687 and termed 
PR687N was amplified from the same hPR-B template using the following primers: (1) 
5’ ACTGTATCGCCGGAATTCATGACTGAGCTGAAGGCAAAG 3’ (containing the 
EcoRI recognition sequence, Kozak sequence, and appropriate base pairs of hPR-B 
cDNA) and (2) 5’ ACGGATCCCCGGGAATTCTGGTGGAATCAACTGTATGTC 3’ 
(containing the EcoRI recognition sequence, Kozak sequence, and appropriate base pairs 
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of hPR-B cDNA). The resulting PCR product was cloned into the DBD empty vector 
between the EcoRI site and processed in a similar manner as above.  
AD-AKAP-Brx was constructed by amplification of the nuclear localization 
sequence and VP16 activation domain from pNLVP16. The resulting fragment was fused 
to the open reading frame of the 1.8 kb AKAP-Brx cDNA by overlap amplification and 
subcloned into the mammalian expression vector pBK-RSV as described previously.
45
 
Constructs were tested for expression of full-length proteins by Western Blot 
analysis of extracts of transfected cells, using anti-GAL4 DNA binding domain and anti-
VP16 antibodies (Santa Cruz). Constructs were also partially sequenced for confirmation. 
The author is grateful to Alexandra Poch for her help in generating these plasmids. 
Ex vivo binding studies (Mammalian-2-Hybrid System)—Cells were grown in 24-
well plates to 50% confluence prior to HilyMax (Dojindo) transfection with 500 ng AD-
AKAP-Brx, 100 ng DBD-PR(687C) or DBD-PR(687N), and 100 ng GAL4-luciferase 
reporter. Six hours after transfection cells were treated with 1 uM progesterone and were 
harvested 24 h thereafter.  
 Statistical Analysis—Statistical analysis was carried out by Student’s t test for 
unpaired samples with the two-tailed p value. All experiments were repeated at least 
twice, and representative results are shown in the figures. 
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Results 
 
 AKAP-Brx Enhances Ligand-dependent Transcriptional Activation by PR-B—
Given our previous observations that AKAP-Brx enhances ligand-dependent 
transcriptional activation by several nuclear hormone receptors, including ER-α45, ER-β46 
and GR
47
, we wanted to test whether AKAP-Brx expression could also affect the ability 
of PR-B to activate a reporter. We first tested Cos7 cells, which are devoid of both 
endogenous AKAP-Brx as well as nuclear progesterone receptors, as they constituted a 
“clean” system in which to isolate the functions of our proteins of interest. Two different 
hormone-responsive promoters were utilized—one specific to progesterone (PRE-
luciferase) and one highly sensitive to steroid hormones (MMTV-luciferase)
49,50—to test 
the robustness of the system. As expected, transfection of PR-B alone into Cos7 cells 
resulted in several fold ligand-dependent activation of the PRE-luciferase reporter (Fig. 
1A, solid black bar) and of the MMTV-luciferase reporter (Fig. 1B, solid black bar) in 
Cos7 cells. Co-transfection of an expression vector for full-length AKAP-Brx enhanced 
ligand-dependent transactivation by PR-B almost two-fold for PRE-luciferase (Fig. 1A, 
hashed black bar, p< 0.01) and five-fold for MMTV-luciferase (Fig. 1B, hashed black 
bar, p < 0.0001). In the absence of ligand, no induction of luciferase activity was 
observed (Fig. 1A and 1B, hashed white bars). These results suggest that the full level of 
activity of PR-B in the presence of AKAP-Brx was dependent on activation of the 
receptor by ligand binding. We also tested the specificity of AKAP-Brx action by 
assessing the ability of Brx to activate the basal promoters TA-luciferase and TK-
luciferase. AKAP-Brx failed to activate these basal promoters (Fig. 1A and 1B, four 
right-most bars). Finally, we tested this paradigm in a line of immortalized uterine 
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leiomyoma cells, which were derived from human fibroid tissue from surgical specimens. 
Previous research indicates that gene expression profiles of these cells closely resemble 
the parent cells.
51
 Once again, we confirmed that co-transfection of AKAP-Brx enhanced 
ligand-dependent gene activation by PR-B by four-fold for the PRE-luciferase reporter 
(the weaker and more specific of the two hormone responsive luciferase promoters based 
on the Cos7 experiments) (p < 0.01) (Fig. 1C).  
 Silencing of AKAP-Brx expression via RNA-interference decreases the activation 
of an endogenous progesterone responsive gene by progesterone in a dose-dependent 
manner—The activity of alkaline phosphatase, a gene known to be progesterone 
responsive, in PR+ T47D breast cancer cells was reduced by 50% in the presence of 
AKAP-Brx interference RNA, when these cells were treated with varying amounts of 
progesterone. The effect was most pronounced with increasing amounts of the hormone, 
from 1 to 40 nM. These results suggest that expression of AKAP-Brx is necessary for the 
full activation of this progesterone-responsive gene in the presence of a wide range of 
progesterone concentrations (Fig. 2).  
  The C-terminal of PR binds to AKAP-Brx in-vitro. To test whether PR could bind 
directly to AKAP-Brx, a fragment of PR corresponding to amino acids 687 through the C 
terminal (amino acid 933) was created via PCR amplification of the full length hPR-B 
bacterial plasmid and in vitro transcribed-translated in the presence of S-35 labeled 
methionine. This fragment, designated PR687C, is common to both PR-A and PR-B and 
contains the AF-2 activation function of the protein as well as the hormone binding 
domain, as illustrated in Figure 3A. In parallel, GST-AKAP-Brx fusion chimeras were 
generated from bacterial plasmids and immobilized on sepharose beads. Two chimeras 
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were proposed: a full length AKAP-Brx construct (designated “FT’) and a fragment 
corresponding to region 5 of the protein (designated “R5”). R5 contains the leucine-rich 
motif (LXXLL) of AKAP-Brx, which has been previously shown to bind the nuclear 
hormone receptors ER-α, ER-β, and GR. This domain has been therefore designated a 
nuclear-receptor-interacting domain (NRID). The construction of AKAP-Brx chimeras is 
illustrated in Figure 3A. Results of the pull down assay demonstrate that PR687C bound 
to both full-transcript AKAP-Brx as well as the smaller, NRID containing, fragment. 
PR687C did not bind to empty non-chimeric glutathione transferase (GST-O) 
immobilized on sepharose beads (Fig. 3A). As a negative control, radiolabeled luciferase 
failed to bind to either full-length or truncated AKAP-Brx (Fig. 3B). As previously 
reported, radiolabeled estrogen receptor did bind to both AKAP-Brx chimeras (Fib. 3C). 
 AKAP-Brx and the C-terminal of PR interact in mammalian cells. Next, we tested 
whether AKAP-Brx and PR687C could interact ex-vivo in mammalian cells. To this end, 
the PR687C fragment was fused to a GAL4 DNA binding domain (DBD-PR687C) and 
transfected into Cos7 cells. In a similar fashion, AKAP-Brx was fused with the VP16 
activation domain (AD-AKAP-Brx) and co-transfected into the cells. Results demonstrate 
that DBD-PR687C by itself can activate a GAL4 luciferase several fold in the presence of 
progesterone ligand. This is not surprising as PR687C contains a hormone-binding-
domain as well as an intrinsic activation domain (AF-2), which, when coupled to the 
GAL4 DBD, are sufficient to induce GAL4-luciferase activity. Co-transfection of AD-
AKAP-Brx doubled this activation profile (p < 0.05), suggesting that the two proteins 
interact directly within live cells. Interestingly, this effect was only seen in the presence 
of progesterone, suggesting that AKAP-Brx and PR interaction is dependent upon 
19 
 
hormone binding (Fig. 4A). On the contrary, when a PR687N construct (expressing 
amino acids 1-687 from the N terminal of PR-B) fused to the GAL4-DBD was tested in 
the same manner, it failed to induce ligand-dependent receptor activity and was not 
influenced by co-transfection of AD-AKAP-Brx (Fig. 4B). This implies that the 
hormone-binding-domain-containing, C terminal region of PR is necessary for interaction 
with AKAP-Brx. It should be noted that activation of luciferase in the presence of DBD-
PR687N is higher than the baseline activation profile of the unfused GAL-DBD control. 
This could be due to the actions of AF-1 and/or AF-3 contained in PR687N; however, 
this activation profile is unaffected by either progesterone ligand or by co-expression of 
AKAP-Brx. Expression of the transfected fusion proteins (AD-AKAP-Brx, DBD-
PR687C and DBD-PR687N) in Cos7 cells was confirmed by immunohistochemical 
detection using antibodies directed against VP16 or GAL4 (data not shown). 
 AKAP-Brx Signaling to PR-B Does Not Involve p38 MAPK—Analogous to other 
members of the steroid receptor superfamily, progesterone receptors are highly 
phosphorylated and therefore sensitive to growth factor-initiated signaling pathways. We 
previously reported that AKAP-Brx augments ligand-dependent activity of ER-β via a 
p38 MAPK dependent pathway.
46
 We thus asked whether AKAP-Brx may signal to PR-
B through this pathway as well. The pyridinyl imidazole compounds SB202190 and 
SB203580 inhibit the α and β isoforms of p38 MAPKs by a mechanism involving direct 
binding to the kinases.
53
 In our transient transfection system using PR-B and the MMTV-
luciferase reporter, co-transfection of AKAP-Brx enhanced ligand-dependent activity of 
PR-B to levels 15-fold that of baseline activation (Fig. 5A, left-most dark bar), consistent 
with the activation profile seen in Fig 1B. Addition of either 2 uM SB202190 or 10 uM 
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SB203580 did not affect the enhancement of ligand-dependent activity of PR-B by Brx 
(Fig. 5A, center and right-most dark bars), suggesting that p38 MAPK activity is not 
required for enhancement of ligand-dependent activity of PR-B. In control experiments, 
the same concentration of inhibitors effectively inhibited p38 MAPK phosphorylation in 
sorbitol-shocked cells (Fig. 5B). 
 AKAP-Brx Activates PR-B by a p42/44 MAPK (ERK1/2) Dependent Pathway—
because activation of PR-B by Brx did not appear to involve p38 MAPK pathways, we 
tested whether the enhancement of PR-B activity by Brx could involve an alternative 
phosphorylation pathway. PR-B has been shown to be activated in a ligand-dependent 
manner by a mechanism involving phosphorylation of Ser 294 residue through the Ras-
Raf-p44/42 MAPK (ERK1/ERK2) signaling pathway.
25
 It has also been shown that the 
Rho protein Cdc42 can activate ERK2 in cooperation with Raf.
54
 We therefore tested 
whether activation of PR-B by Brx involves ERK1/2. Dual specificity mitogen-activated 
protein kinase kinases (MEK) activate ERK by phosphorylating specific Thr and Tyr 
residues. The inhibitor UO126 is thought to block activation of ERK
55
 by binding to 
inactive MEK1 and blocking activation by upstream kinases.
16
 In our transient 
transfection system using PR-B expressed as a bacterial plasmid and the MMTV-
luciferase reporter, transfection of PR-B activated luciferase expression several fold in 
the presence of ligand compared with control transfections lacking ligand. Co-
transfection of AKAP-Brx enhanced ligand-dependent activity of PR-B over 2-fold (Fig. 
6A). Addition of 1 uM UO126 inhibited activation of PR-B by AKAP-Brx by 40% (p < 
0.0001), suggesting that ERK1/2 activity is required for enhancement of ligand-
dependent activity of PR-B by AKAP-Brx. In control experiments, 1 uM UO126 
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effectively inhibited ERK1/2 phosphorylation induced by serum growth factors (data not 
shown).  
22 
 
Discussion 
 
Previously, AKAP-Brx has been reported to activate several nuclear hormone 
receptors including estrogen receptors alpha
45
 and beta
46
 and glucocorticoid receptor
47
. 
Here we show for first time that AKAP-Brx also increases ligand-dependent gene 
activation by PR-B. Our results are reproducible in different cell types (Cos7, fibroids) 
and with different progesterone-responsive reporter genes. Conversely, silencing of 
AKAP-Brx via RNA interference decreases expression of progesterone-dependent genes 
in PR+ cells. While we don’t know the exact mechanism through which AKAP augments 
PR-B action, it appears to require p42-44 MAPK (ERK1/2). This is in contrast to AKAP-
Brx- mediated activation of ER, which required p38 MAPK signaling, but not ERK1/2.
46
 
In-vitro and ex-vivo studies suggest that there is direct interaction between AKAP-Brx 
and PR-B, as is evident for the estrogen receptors
45,46
 as well as the glucocorticoid 
receptor.
47
 Furthermore, direct binding occurs via a LXXLL-containing nuclear receptor 
interaction domain (NRID) on AKAP-Brx and through PR’s conserved ligand binding C 
terminus.  
A working model integrating the multiple known functions of AKAP-Brx with 
the newfound data of its interaction with PR-B is proposed in Figure 7. In this model, 
AKAP-Brx is conceptualized as a scaffold protein, capable of bringing in close 
proximity, at the sub-cellular level, the different players involved in extracellular signal 
transduction—which includes both mechanical signals (notably matrix stiffness) and 
extracellular growth factors—with steroid hormone signaling. On the one hand, matrix 
stiffness activates Rho/ROCK and ERK pathways, ultimately leading to cytoskeletal 
tension, focal adhesion complex formation, and growth. At the same time, AKAP-Brx 
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binds PR via its LXXLL containing nuclear receptor interaction domain (NRID) when 
the receptor is bound to progesterone. It subsequently augments PR-B transcriptional 
activity through ERK1/2 phosphorylation. While we do not know the exact mechanism 
underlying the enhancement of PR-B activity by ERK1/2, we hypothesize that it may 
involve signaling via Rho. If this is the case, it is possible that, in fibroids, activation of 
Rho—by increased matrix stiffness and/or AKAP-Brx over-expression—enhances ERK 
activity, leading to PR phosphorylation and increased transcription of genes involved in 
cellular proliferation. AKAP-Brx therefore provides a possible point of convergence 
between Rho-mediated (mechanical) signaling and progesterone-mediated (soluble) 
signaling in fibroids. In this paradigm, the effects of even low-to-normal levels of 
circulating progesterone would become amplified through Rho-ERK-PR transduction 
pathways, raising the interesting possibility that fibroid cells might be relatively 
insensitive to reductions in circulating progesterone, a condition that could contribute to 
fibroid pathogenesis and survival. This would explain why fibroid development, though 
favored by high-progesterone states, is not restricted to such periods and why some 
women do not respond to treatment with SPRMs.  
This study has several limitations. First, all experiments were conducted in cell 
culture. Ideally, our findings should be extended to in-vivo mouse models. Second, 
immortalized fibroid cells lose their endogenous progesterone receptor activity and we 
thus had to transfect exogenous human PR-B in order to demonstrate our findings. 
Working with primary cell cultures may bypass this problem in the future. However, the 
lack of endogenous PR in fibroid cells did allow us to isolate our findings to the PR-B 
isoform, which would otherwise have been difficult. Third, while we were able to isolate 
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the AKAP-Brx binding sites of PR-B to amino acids 687 through 933, we were not able 
to produce full-length progesterone receptor B for the purpose of our GST-pull-down 
binding studies. Reversing the direction of the constructs (GST-PR and S35-labeled 
AKAP-Brx) may be an alternative approach. Finally, the role of AKAP-Brx’s PKA-
binding and Rho-GEF domains need to be examined more directly in relation to MAPK 
and PR signaling.  
Certainly, further studies are needed to continue to elucidate the relationship 
between progesterone, AKAP-Brx and MAPK, and how their signaling interactions 
culminate in increased leiomyoma growth. We hope that, in time, the augmenting 
understanding of this important topic may lead to new treatments for fibroids and 
potentially other highly prevalent uterine conditions such as pre-term birth, which affect 
millions world-wide.  
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Figure 1 
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Figure 1. AKAP-Brx augmented ligand-dependent gene-activation by progesterone 
receptor B. (a) Cos7 cells plated in 24-well plates were transiently transfected with 
expression vectors for AKAP-Brx (0.3-0.5 ug), PR-B (25 ng) and a luciferase reporter 
containing a progesterone-response-element (PRE) promoter (0.3-0.5 ug). A luciferase 
reporter containing the basal TA promoter was used as a control. Amount of transfected 
DNA was kept constant by the addition of empty vector. After 24 hours, cells were 
treated with 40 nM progesterone and assayed for luciferase activity 24 hours later. 
Expression of AKAP-Brx resulted in a 1.7 fold increase in PRE-luciferase activity in the 
presence of progesterone (**p < 0.01), while no effect was seen in the absence of 
progesterone or with the TA-Luc basal promoter. (b) Cos7 cells were transfected with a 
luciferase reporter plasmid containing the hormone responsive mouse mammary tumor 
virus (MMTV) promoter (0.3 to 0.5 ug) and otherwise handled as above. A luciferase 
reporter containing the basal tirosine-kinase (TK) promoter was used as a control. 
Expression of AKAP-Brx resulted in a 5 fold increase in MMTV-luciferase activity in the 
presence of progesterone (***p < 0.0001), while no effect was seen in the absence of 
progesterone or with the TK-luciferase basal promoter. (c) Fibroid cells were transfected 
with PRE-luciferase and handled as above. Expression of AKAP-Brx resulted in a 4 fold 
increase in PRE-luciferase activity in the presence of progesterone (**p < 0.01), while no 
effect was seen in the absence of progesterone or with the TA-Luc basal promoter. 
Luciferase values represent fold-activation (mean) over control (the respective luciferase 
reporter in the absence of ligand and AKAP-Brx). Each graph represents data from four 
experiments conducted in triplicate, n = 12 per bar. Error bars represent standard error of 
the mean (SEM). 
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Figure 2 
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Figure 2. Silencing expression of AKAP-Brx via RNA interference reduced 
activation of an endogenous progesterone-responsive gene in the presence of 
progesterone hormone, in a dose-dependent manner. T47D cells were seeded in 24-
well plates and grown to 30-50% confluence in phenol-red-free media supplemented with 
charcoal-stripped-serum. Cells were transfected with 20 pmol AKAP-Brx siRNA or 
equal amounts of scrambled negative control siRNA (ASN) per well. After 24 hours, 
increasing amounts of progesterone (0, 0.5, 1.0, 5.0, 10, 20 or 40 nM) were added as 
indicated. Cells were lysed and assayed for activity of the PR-controlled gene alkaline 
phosphatase after an additional 24 hours. 
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Figure 3 
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Figure 3. Interaction between AKAP-Brx and PR in vitro.  (a) GST-AKAP-Brx 
chimeric fusion proteins were created by subcloning AKAP-Brx (full length (FT) and 
region 5 fragment (R5)) into the bacterial expression plasmid pGEX2TKB. Fragments of 
PR from amino acid 687 to the C terminus were in vitro transcribed-translated in the 
presence of S-35 labeled methionine. 35S-methionine labeled PR was incubated with 
bacterially expressed GST-AKAP-Brx transcripts (FT or R5), or GST alone (GST-0), 
coupled to glutathione-Sepharose beads. Bound proteins were resolved using SDS± 
PAGE and visualized by autoradiography. Results show the PR687C bound to both full 
transcript AKAP-Brx and R5 AKAP-Brx, but not to the negative control GST-O. (b) 
Negative control: Luciferase did not bind to AKAP-Brx. (c) Positive control: As 
previously reported, ER bound to AKAP-Brx.
45
 Representative results of 6 experiments 
are shown.  
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Figure 4 
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Figure 4. Interaction between AKAP-Brx and PR in mammalian cell culture. 
Expression plasmids encoding the LXXLL-motif-containing Region 5 of AKAP-Brx 
fused to the VP16 transcription activation domain (AD) and/or PR constructs fused to the 
GAL4 DNA binding domain (DBD) were transfected as indicated into Cos7 cells 
together with a GAL4-luciferase reporter (present in all lanes). (a) The ligand-binding 
region of PR (from amino acid 687 to the C terminus) was tested against AKAP-Brx. 
Transfection of DBD-PR(687C) alone resulted in hormone-dependent activation of the 
luciferase reporter, which was an expected finding given the intrinsic activation domain 
contained by this region of PR (AF-2). Co-transfection of AKAP-Brx doubled this 
activation (*p < 0.05), suggesting that the two proteins can interact directly in cells.  (b) 
The N terminal region of PR (from amino acid 1 to amino acid 687) was tested against 
AKAP-Brx. As expected, there was no hormone-dependent activation of luciferase, as the 
N-terminal region of PR does not contain a hormone-binding-domain. While the basal 
luciferase expression was higher when DBD-PR(687N) was transfected (over the empty 
DBD and AD vectors) this increase was non-specific and was not enhanced by co-
transfection of AD-AKAP-Brx, suggesting that AKAP-Brx requires the C terminal of PR 
to bind the protein. For both graphs, luciferase activity is depicted as fold induction 
(mean) over control (reporter and empty vectors). Three experiments were performed in 
triplicate, n=9 per bar. Errors bars represent SEM. Expression of transiently transfected 
fusion proteins (AD-AKAP-Brx, DBD-PR687C and DBD-PR687N) in Cos7 cells was 
confirmed by immunohistochemical detection using antibodies directed against VP16 or 
GAL4 (data not shown). 
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Figure 5 
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Figure 5. Augmentation of PR-B activity by AKAP-Brx was not affected by the 
inhibition of p38 MAPK activity (a) the p38 MAPK inhibitors SB202190 and 
SB203580 did not inhibit the  activity of AKAP-Brx. Cos7 cells were transfected with 0.5 
ug of a MMTV-luciferase reporter plasmid and 0.5 ug of an expression vector for AKAP-
Brx, along with 25 ng of hPR-B. SB202190 (2 uM), SB204580 (10 uM) or DMSO 
vehicle were added as indicated. Cells were treated with 40 nM progesterone versus 
EtOH vehicle as shown. Luciferase values represent -fold activation (with activation 
given by MMTV-luciferase in the absence of ligand arbitrarily assigned a value of 1.0) 
from three experiments performed in triplicate or quadruplicate, n=10 per bar. Error bars 
represent SEM. (b) Inhibitor efficacy was tested by sorbitol shocking cells in the 
presence or absence of the respective inhibitor. Cell lysates were resolved by SDS-
PAGE, blotted in PVDF and probed for p38 MAPK (phospho-specific and pan). Relative 
protein concentrations were analyzed by densitometry as shown at right. Results 
demonstrate that both inhibitors decreased phosphorylated p38 MAPK by 70% compared 
to the no-inhibitor + sorbitol condition. Representative results of three experiments are 
shown.  
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Figure 6 
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Figure 6. Activation of PR-B by AKAP-Brx was dependent on p42/44 (ERK1/2) 
activity. (a) Activation of PR-B by AKAP-Brx was inhibited by the MEK inhibitor 
UO126 at 1 uM and 10 uM doses. Cos7 cells were transfected with 0.5 ug of a MMTV-
luciferase reporter plasmid and expression vectors for hPR-B (25 ng) and AKAP-Brx (0.5 
ug) or the same amounts of empty expression vectors. Progesterone (40 nM, dark bars) or 
vehicle control (EtOH, light bars) and increasing doses of UO126 or control (DMSO) 
were added as indicated. Cells were harvested after 24 h. Luciferase values represent 
fold-activation (mean) over control (MMTV-luciferase in the absence of ligand, inhibitor, 
and AKAP-Brx plasmid) compiled from two experiments conducted in duplicate for the 
0.1 uM UO126 and 10 UO126 conditions (n=4 per bar) and five experiments conducted 
in triplicate for the DMSO and 1 uM UO126 conditions (n=15 per bar). Error bars 
represent SEM. (b) As a control, the same paradigm as in (a) was tested using the basal 
tk-luciferase, which yielded no luciferase activity for any condition, as expected.  
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Figure 7 
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Figure 7. Working model of the relationship between AKAP-Brx, Progesterone 
Receptor, and ERK signaling pathways. AKAP-Brx is a scaffold protein which 
localizes at the subcellular level the different players involved in extracellular signal 
transduction (both mechanical signals and growth factor signals) and steroid hormone 
signaling. AKAP-Brx binds PR via its LXXLL containing nuclear receptor interaction 
domain (NRID) when the receptor is bound to progesterone. It subsequently augments 
PR-B transcriptional activity through a pathway involving ERK1/2. While the 
mechanism underlying the enhancement of PR-B activity by ERK1/2 remains unknown, 
it may involve signaling via Rho (hashed arrow). Abbreviations: cAMP = cyclic 
adenosine monophosphate. PKA = protein kinase A. CI and CII = catalytic domains 1 
and 2. RI and RII = regulatory domains 1 and 2. Ht31 = PKA binding domain. GEF = 
guanine-exchange factor domain. NRID = nuclear receptor interaction domain. PR = 
progesterone receptor. PRE = progesterone response element. 
